Repligen | RGEN - Current Liabilities

Stock Price
135.68
Daily Change
-1.54 -1.12%
Monthly
-20.17%
Yearly
-14.66%
Q1 Forecast
131.47

Repligen reported $131.14M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Agilent USD 2.35B 455M Sep/2025
Align Technology USD 1.92B 46.45M Dec/2025
Bio Techne USD 140.43M 4.12M Dec/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Bruker USD 1.28B 11.1M Dec/2025
Charles River Laboratories USD 1.12B 1.57M Dec/2025
Danaher USD 6.81B 483M Dec/2025
Dentsply International USD 1.4B 239M Sep/2025
Exact Sciences USD 641.15M 56.89M Dec/2025
General Electric Aerospace USD 38.98B 1.78B Dec/2025
Henry Schein USD 3.15B 142M Sep/2025
Illumina USD 1.59B 377M Dec/2025
IQVIA Holdings USD 8.34B 170M Dec/2025
Mettler Toledo International USD 1.2B 5.99M Dec/2025
Myriad Genetics USD 148M 51.9M Sep/2025
OraSure Technologies USD 40.25M 2.1M Sep/2025
Pacific Biosciences Of California USD 63.21M 3.45M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Repligen USD 131.14M 8.12M Sep/2025
Revvity USD 1.33B 108.5M Dec/2025
Standard Biotools USD 107.96M 9.94M Sep/2025
Thermo Fisher Scientific USD 15.19B 301M Dec/2025
Waters USD 1.24B 11.8M Dec/2025
West Pharmaceutical Services USD 654.9M 19.5M Dec/2025